Indiana University School of Medicine cancer researchers who have been working to lessen the side effects caused by chemotherapy have been awarded $2.3 million to continue their studies. Jill Fehrenbacher and Mark Kelley are recipients of the five-year grant (1R01CA231267) from NCI, which will enable them to continue their studies on chemotherapy-induced peripheral neuropathy. The […]
The National Coalition for Cancer Survivorship presented the third annual Ellen L. Stovall Award for Innovation in Patient-Centered Cancer Care to Gay Crawford, founding director of Cancer CAREpoint, and Norman Coleman, senior investigator at NCI. Since her diagnosis of breast cancer at age 30, Crawford spent the last 44 years playing a leadership role in […]
A husband-and-wife team at the University of Virginia Cancer Center have been awarded more than $1.8 million from NCI (R01 CA214594-01A1) for their effort to improve radiation therapy and breast surgery for patient with early-stage breast cancer. Radiation oncologist Timothy Showalter and breast cancer surgeon Shayna Showalter are leading an interdisciplinary effort to evaluate a […]
Oct. 25, we heard more about President Trump's plan to save health care dollars through a variety of Medicare pilot programs and index pricing.
Heinz Von Foerster, the renowned Austrian-American physicist and cybernetics scholar, declared that “information can be considered as order wrenched from disorder.1” Ever-increasing amounts of digital data and new computational tools promise that technological developments such as artificial intelligence (AI) will bring order, clarity, and new solutions in multiple areas—from transportation to criminal justice.
Arti Hurria, a pioneer of geriatric cancer care at City of Hope, died Nov. 7 in a traffic accident. She was 48.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Merck, known as MSD outside the United States and Canada, announced the FDA has approved Keytruda, Merck's anti-PD-1 therapy, in combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of patients with metastatic squamous non-small cell lung cancer based on results from the KEYNOTE-407 trial.
Taiho Oncology, Inc. announced the FDA has accepted and granted priority review for the supplemental New Drug Application for Lonsurf (trifluridine/tipiracil, TAS-102) as a treatment for patients with previously treated, advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.
Genentech announced the randomized phase III CLL14 study, which evaluated fixed-duration Venclexta (venetoclax) in combination with Gazyva (obinutuzumab) in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (progression-free survival as assessed by investigator) compared to standard-of-care Gazyva plus chlorambucil.
